Company: BIAF
Filing Date: 2025-04-22
Form Type: 424B3
Source: 0001641172-25-005598
Chunk: 20

Company: bioAffinity Technologies, Inc.
Filing Date: 2025-04-22
Form: 424B3
Chunk 20
---
. Our revenue and income potential for the clinical laboratory
is unproven and our business model is continually evolving. We are subject to the risks inherent to the operation of a new business enterprise
and cannot assure you that we will be able to successfully address these risks.

Risks Related to this Offering

Resales of our Common Stock in the public market by our stockholders as a result of this offering may cause the market price of our Common Stock to fall.

We are registering Common Stock issuable upon the
exercise of the Common Warrants. Sales of substantial amounts of our Common Stock in the public market, or the perception that such sales
might occur, could adversely affect the market price of our Common Stock. The issuance of new shares of Common stock could result in resales
of our Common Stock by our current stockholders concerned about the potential ownership dilution of their holdings. Furthermore, in the
future, we may issue additional shares of Common Stock or other equity or debt securities exercisable or convertible into Common Stock.
Any such issuance could result in substantial dilution to our existing stockholders and could cause our stock price to decline.

Investors who buy shares at different times will likely pay different prices.

Investors who purchase shares in this offering at
different times will likely pay different prices, and so may experience different levels of dilution and different outcomes in their investment
results.

This offering may cause the trading price of our Common Stock to decrease.

The price per share of our Common Stock, together
with the number of shares of Common Stock we propose to issue upon exercise of the Common Warrants and ultimately will issue if this offering
is completed, may result in an immediate decrease in the market price of our Common Stock. This decrease may continue after the completion
of this offering. Sales of substantial amounts of our Common Stock in the public market, or the perception that such sales might occur,
could adversely affect the market price of our Common Stock.

Our management will have broad discretion over the use of the net proceeds from this offering, you may not agree with how we use the proceeds, and the proceeds may not be invested successfully.

We have not designated any portion of the net proceeds
from the exercise of Common Warrants to be used for any particular purpose. Accordingly, our management will have broad discretion as
to the use of the net proceeds and you will be relying on the judgment of our management with regard to the use of these net proceeds,
and you will not have the opportunity, as part of your investment decision, to